Skip to main content

Advertisement

Table 3 Clinical outcomes of non-diabetic patients with STEMI based on MAGE and ABG

From: Comparison of in-hospital glycemic variability and admission blood glucose in predicting short-term outcomes in non-diabetes patients with ST elevation myocardial infarction underwent percutaneous coronary intervention

  MAGE (mmol/L) ABG (mmol/L)
≤3.26 >3.26 p ≤7.80 >7.80 p
n 170 86   170 86  
Peak CK (U/L) 905 (300–4077) 1290 (471–4658) 0.020 897 (300–4428) 1372 (398–4658) 0.039
GRACE score 140 ± 33 152 ± 34 0.005 141 ± 34 150 ± 33 0.036
MACE 20 (13.5) 30 (31.4) 0.001 26 (15.9) 24 (26.7) 0.046
 Cardiac death 1 (0.6) 5 (5.8) 0.017 2 (1.2) 4 (4.7) 0.100
 New-onset MI 3 (1.8) 5 (5.8) 0.123 4 (2.4) 4 (4.7) 0.448
 Acute HF 4 (2.4) 11 (12.8) 0.001 7 (4.1) 8 (9.3) 0.156
 TVR 12 (7.1) 9 (10.5) 0.346 13 (7.6) 8 (9.3) 0.637
  1. Data are mean ± SD and number (%)
  2. STEMI ST elevated myocardial infarction, MAGE the mean amplitude of glycemic excursions, ABG admission blood glucose, CK creatine kinase, MACE major adverse cardiac events, MI myocardial infarction, HF heart failure, TVR repeat target vessel revascularization